Rosuvastatin Reverses Hypertension-Induced Changes in the Aorta Structure and Endothelium-Dependent Relaxation in Rats Through Suppression of Apoptosis and Inflammation

Abstract: Vascular remodeling is one of the most critical complications caused by hypertension. Previous studies have demonstrated that rosuvastatin has anti-inflammatory, antioxidant, and antiplatelet effects and therefore can be used to treat cardiovascular disease. In this study, we explored the beneficial effects of rosuvastatin in reversing aortic remodeling in spontaneously hypertensive rats. After treating with different doses of rosuvastatin, its antilipid, antiapoptosis, and anti-inflammatory effects were determined. We also examined whether rosuvastatin can improve the structure and function of the aorta. We found that rosuvastatin treatment of spontaneously hypertensive rats for 2 months at 2 different doses can effectively reduce the media thickness of the aorta compared with the control group. Similarly, rosuvastatin improved the vascular relaxation function of the aortic rings at a high level of acetylcholine in vitro. Mechanistically, it was found that rosuvastatin increased the expression of endothelial nitric oxide synthase and plasma nitrite/nitrate levels. Besides, rosuvastatin suppressed the apoptosis and inflammation and upregulated the expression of gap-junction complex connexin 43 both in media and endothelium. Finally, rosuvastatin inhibited the AT1R/PKCα/HSP70 signaling transduction pathway. In summary, these findings demonstrated that rosuvastatin could improve the vascular structure and function mainly by increasing endothelial nitric oxide synthase expression and preventing apoptosis and inflammation. This study provided evidence that rosuvastatin has beneficial effects in reversing the remodeling of the aorta due to hypertension.

[1]  C. Antoniali,et al.  Reduced caveolae density in arteries of SHR contributes to endothelial dysfunction and ROS production , 2019, Scientific Reports.

[2]  Q. Cheng,et al.  Atorvastatin alleviates early hypertensive renal damage in spontaneously hypertensive rats. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  Aladeen Alloubani,et al.  Hypertension and diabetes mellitus as a predictive risk factors for stroke. , 2018, Diabetes & metabolic syndrome.

[4]  Ye-li Li,et al.  Icariside II attenuates myocardial fibrosis by inhibiting nuclear factor-κB and the TGF-β1/Smad2 signalling pathway in spontaneously hypertensive rats. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[5]  Jiamei Wang,et al.  Mechanisms in hypertension and target organ damage: Is the role of the thymus key? (Review) , 2018, International journal of molecular medicine.

[6]  Pengbo Wang,et al.  Rosuvastatin improves myocardial hypertrophy after hemodynamic pressure overload via regulating the crosstalk of Nrf2/ARE and TGF‐&bgr;/ smads pathways in rat heart , 2018, European journal of pharmacology.

[7]  P. Rossignol,et al.  Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats , 2018, Journal of hypertension.

[8]  Aizhong Wang,et al.  Propofol induces excessive vasodilation of aortic rings by inhibiting protein kinase Cβ2 and θ in spontaneously hypertensive rats , 2017, British journal of pharmacology.

[9]  K. Ma,et al.  Role of gap junctions in the contractile response to agonists in the mesenteric resistance artery of rats with acute hypoxia. , 2017, Molecular medicine reports.

[10]  Liangming Liu,et al.  Involvement of connexin43 phosphorylation and gap junctional communication in vasopressin-induced ROCK-dependent vasoconstriction after hemorrhagic shock. , 2017, American journal of physiology. Cell physiology.

[11]  J. Redón,et al.  Impact of hypertension on mortality and cardiovascular disease burden in patients with cardiovascular risk factors from a general practice setting: the ESCARVAL-risk study , 2016, Journal of hypertension.

[12]  Mahboob Rahman,et al.  Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[13]  H. Nathoe,et al.  Hypertensive Target Organ Damage and Longitudinal Changes in Brain Structure and Function: The Second Manifestations of Arterial Disease-Magnetic Resonance Study. , 2015, Hypertension.

[14]  P. Vanhoutte,et al.  α1‐Adrenoceptor activation of PKC‐ε causes heterologous desensitization of thromboxane receptors in the aorta of spontaneously hypertensive rats , 2015, British journal of pharmacology.

[15]  Limei Liu,et al.  Protein kinase C&bgr; mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries , 2015, Journal of hypertension.

[16]  Hong Wei Xu,et al.  Effects of rosuvastatin correlated with the down-regulation of CYP4A1 in spontaneously hypertensive rats. , 2015, Microvascular research.

[17]  R. Touyz,et al.  Angiotensin II and Vascular Injury , 2014, Current Hypertension Reports.

[18]  P. Tchounwou,et al.  The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling , 2014, International journal of inflammation.

[19]  R. Magness,et al.  Gap junction regulation of vascular tone: implications of modulatory intercellular communication during gestation. , 2014, Advances in experimental medicine and biology.

[20]  V. Dosenko,et al.  Correction of vascular hypercontractility in spontaneously hypertensive rats using shRNAs-induced delta protein kinase C gene silencing. , 2013, European journal of pharmacology.

[21]  Lei Zhang,et al.  Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats. , 2013, Molecular medicine reports.

[22]  S. Taddei,et al.  Rosuvastatin prevents angiotensin II‐induced vascular changes by inhibition of NAD(P)H oxidase and COX‐1 , 2013, British journal of pharmacology.

[23]  A. El-Yazbi,et al.  Ca2+ sensitization due to myosin light chain phosphatase inhibition and cytoskeletal reorganization in the myogenic response of skeletal muscle resistance arteries , 2013, The Journal of physiology.

[24]  Gang Zhao,et al.  Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway , 2012, Journal of cellular and molecular medicine.

[25]  Chien-Hsing Wu,et al.  The role of nitric oxide on rosuvastatin-mediated S-nitrosylation and translational proteomes in human umbilical vein endothelial cells , 2012, Proteome Science.

[26]  J. Chalmers,et al.  Mortality patterns in hypertension , 2011, Journal of hypertension.

[27]  L. Jing,et al.  Inhibition of Extracellular Signal-Regulated Kinases Ameliorates Hypertension-Induced Renal Vascular Remodeling in Rat Models , 2011, International journal of molecular sciences.

[28]  X. Tian,et al.  Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress , 2011, British journal of pharmacology.

[29]  K. Nose,et al.  Transcriptional induction of MMP-10 by TGF-β, mediated by activation of MEF2A and downregulation of class IIa HDACs , 2010, Oncogene.

[30]  I. Bernátová,et al.  Modulation of connexin-43 by omega-3 fatty acids in the aorta of old spontaneously hypertensive rats. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[31]  F. Luft,et al.  Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion , 2009, Journal of hypertension.

[32]  B. Isakson,et al.  Biological and biophysical properties of vascular connexin channels. , 2009, International review of cell and molecular biology.

[33]  J. Smits,et al.  Prehypertensive Renin-Angiotensin-Aldosterone System Blockade in Spontaneously Hypertensive Rats Ameliorates the Loss of Long-Term Vascular Function , 2007, Hypertension Research.

[34]  D. D. Mosser,et al.  Hsp70 Inhibits Heat-induced Apoptosis Upstream of Mitochondria by Preventing Bax Translocation* , 2005, Journal of Biological Chemistry.

[35]  J. Haefliger,et al.  Contribution of connexins to the function of the vascular wall. , 2004, Cardiovascular research.

[36]  K. Hirata,et al.  A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats , 2002, Journal of hypertension.

[37]  Steven P Jones,et al.  Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. , 2002, Journal of the American College of Cardiology.

[38]  Ernesto L. Schiffrin,et al.  Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis , 2001, Hypertension.

[39]  U. Laufs,et al.  HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species , 2001, Hypertension.

[40]  D. Weiss,et al.  Angiotensin II–Induced Hypertension Accelerates the Development of Atherosclerosis in ApoE-Deficient Mice , 2001, Circulation.

[41]  T. Ogihara,et al.  Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[42]  J. Díez,et al.  Susceptibility to apoptosis measured by MYC, BCL-2, and BAX expression in arterioles and capillaries of adult spontaneously hypertensive rats. , 1999, American journal of hypertension.

[43]  J. Liao,et al.  Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.

[44]  J. Liao.  Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-derived nitric oxide. , 1994, The Journal of biological chemistry.

[45]  P. Hamet,et al.  Enhanced growth-dependent expression of TGF beta 1 and hsp70 genes in aortic smooth muscle cells from spontaneously hypertensive rats. , 1992, Canadian journal of physiology and pharmacology.